Armed forces epidemiological board
Download
1 / 43

LTC John Skvorak - PowerPoint PPT Presentation


  • 321 Views
  • Updated On :

Armed Forces Epidemiological Board. 20 May 2003 Medical Chemical Biological Defense Research Program U.S. Army Medical Research and Materiel Command. LTC John P. Skvorak Director Medical Biological Defense Research Program U.S. Army Medical Research and Materiel Command Phone: 301-619-7889

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'LTC John Skvorak' - elina


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
Armed forces epidemiological board l.jpg
Armed Forces Epidemiological Board

20 May 2003

Medical Chemical Biological Defense Research Program U.S. Army Medical Research and Materiel Command

LTC John P. Skvorak

Director Medical Biological Defense Research Program

U.S. Army Medical Research and Materiel Command

Phone: 301-619-7889

[email protected]


Organizational management execution l.jpg
Organizational Management & Execution

  • On 22 April 2003, USD(AT&L) approved the implementation plan for management of the DoD Chemical & Biological Defense Program (CBDP)

    • Management and integration of CB Defense Science & Technology (S&T) efforts assigned to the Defense Threat Reduction Agency (DTRA)

    • Establishment of a Joint Program Executive Office (JPEO) for the CBDP that reports through the Army Acquisition Executive (AAE) to the Defense Acquisition Executive (DAE)


Protecting warfighters through integration and teamwork l.jpg

Intelligence

  • Agent

  • Delivery System

  • Organization

  • Time

Medical Countermeasures

  • Vaccines & Prophylaxes

  • Diagnostics

  • Therapeutics

Chem/Bio Defense Doctrine

Education & Training

  • Military and Civilian Health Care Providers

  • Electronic Communication

  • Distance Learning

Physical Countermeasures

  • Detection

  • Physical Protection

  • Decontamination

Protecting Warfighters Through Integration and Teamwork


Medical chemical and biological defense research program mission vision l.jpg

Provide medical solutions for military requirements to protect and sustain the force in a Chemical and/or Biological Warfare environment

To Preserve Total Warfighter Effectiveness on a CW/BW Battlefield

Prevent casualties

Provide effective treatment of casualties for rapid return to duty

Provide rapid, far-forward diagnosis of CW/BW disease

Medical Chemical and Biological Defense Research Program Mission & Vision


Intelligence requirements process l.jpg

TEP protect and sustain the force in a Chemical and/or Biological Warfare environment, STARs, Regional , Proliferation, Technology, and other Assessments

RDA and Modernization Plans, Budget

Intelligence Requirements Process

THREAT ASSESSMENTS

  • Prepared in discrete, tailored packages

  • Evaluate impact on users

  • Define mission needs

    REQUIREMENTS

  • Joint Requirements Office for Chemical, Biological, Radiological and Nuclear Defense (JRO-CBRN)

  • Joint Requirements Oversight Council (JROC)

    PROGRAMS

  • Joint Service Materiel Group (JSMG)

  • Defense Threat Reduction Agency (DTRA)/Joint Program Executive Office (JPEO)

  • OSD coordinates/integrates funding requests

ICDs/CDDs/CPDs, CPR, Integrated Priority Lists

All programs driven by validated threats and defined mission needs


Slide6 l.jpg

Medical Biological Defense protect and sustain the force in a Chemical and/or Biological Warfare environment

Business Area Taxonomy

Medical Biological Defense

Countermeasures (CMs)

Diagnostics

Bacteriology

Virology

Toxinology

DTO CB.47 (ImmunoDx)

DTO CB.31 (Brucella)

Diagnostic Technologies

DTO CB.24 (VEE)

DTO CB.32 (Alt. Delivery)

DTO CB.46 (Ricin)

DTO CB.34 (Plague)

DTO CB.54 (Pox Tx)

DARPA Transition

Vaccines

Vaccines

Vaccines

Therapeutics

Therapeutics

Therapeutics

Vaccines

Therapeutics

Genetically Engineered Threats Medical CMs

Diagnostic

Technologies


Mcbdrp locations l.jpg

APG, MD protect and sustain the force in a Chemical and/or Biological Warfare environment

Fort Detrick, MD

Washington, D.C.

MCBDRP Locations

  • Fort Detrick, MD

    • MCBDRP

    • U.S. Army Medical Research Institute of Infectious Diseases

  • Forest Glen Annex, MD

    • Walter Reed Army Institute of Research

    • Naval Medical Research Center

  • Washington D.C.

    • Armed Forces Institute of Pathology

  • Aberdeen Proving Ground, MD

    • U.S. Army Medical Research Institute of Chemical Defense

  • Natick, MA

    • U.S. Army Medical Research Institute of Environmental Medicine


Integration of dod acquisition and fda licensure l.jpg

Research Labs/CBMS Cooperative Management protect and sustain the force in a Chemical and/or Biological Warfare environment

Research Laboratories

BA3

BA4

BA1

BA5

BA2

Milestone A

Milestone B

MilestoneC

Follow-on Production IPR

Component Advanced Development IPR

Basic Research

Applied Research

Production & Deployment

Sustainment & Disposal

Concept & Technology Development

System Development & Demonstration

PROGRAM Vaccine IPTOVERSIGHT

SSC

PSC

PROGRAM

EXECUTION

Consolidated PDT

Proof of Concept

Baseline Product

IdentifyThreatAgent

Characterize ThreatAgent

Identify Vaccine Antigens

DefineAnimalModels

Evaluate Vaccine Technical Approaches

DevelopAssaysandReagents

Define Manufacturing Process

Phase 1 Clinical Trials

FDA Licensure

Pre-IND Activities

IND Application to FDA

ManufactureConsistency Lots

Produce, Store andMaintainVaccineStockpile

Post-MarketingSurveillance

Formulate Multivalent Vaccine (if required)

Phase 2a

ClinicalTrials

Design Surrogate End-point of Clinical Efficacy

Phase 2b ClinicalTrials

Validate Assays

Qualify Assays

SurrogateEfficacyTests

Manufacture cGMP Pilot Lots

Test in Animal Models

Prepare andSubmit BLA

Perform Non-clinical Tests

Characterize Candidates

Manufacture Small-Scale Pilot Lots

Integration of DoD Acquisition and FDA Licensure


Medical biological defense research program l.jpg
Medical Biological Defense Research Program protect and sustain the force in a Chemical and/or Biological Warfare environment


Medical biological defense potential threats l.jpg

Bacteria: protect and sustain the force in a Chemical and/or Biological Warfare environment

Bacillus anthracis (Anthrax)

Yersinia pestis (Plague)

Francisella Tularensis (Tularemia)

Brucella sp. (Brucellosis)

Burkholderia maellei (Glanders)

Coxiella burnetii (Q Fever)

Viruses:

Smallpox

Encephalomyelitis viruses

Ebola

Marburg

Toxins:

Botulinum Toxins (Types A – G)

Staphylococcal Enterotoxins (SEA/B)

Ricin Toxin

Marine Neurotoxins

Mycotoxins

Clostridium perfringens

Medical Biological Defense Potential Threats


Slide11 l.jpg

Bacteriology protect and sustain the force in a Chemical and/or Biological Warfare environment

Task Areas

Objective:Explore the development of candidate prophylactic and therapeutic medical countermeasures (i.e., vaccines, antibiotics and biologics) against validated BW threat agents, using laboratory and appropriate animal models, and to demonstrate their capability for reducing mortality or incapacitation in animal models exposed to predicted or presumed battlefield doses of aerosolized bacterial BW agents.

JFOC(s) addressed:Medical Prophylaxis (OC) – Individual Protection (PC)

Medical Treatment (OC) – Restoration (PC)

*Note: DTO CB.33 Recombinant Protective Antigen (rPA) Anthrax Vaccine Candidate completed in FY02


Cb 33 recombinant protective antigen rpa anthrax vaccine candidate dto completed in fy02 l.jpg
CB.33 Recombinant Protective Antigen (rPA) Anthrax Vaccine Candidate(DTO completed in FY02)

  • Requirement for transition of rPA vaccine candidate out of the tech base and into Technology Development pre-acquisition phase have been met

  • National Institute of Allergy and Infectious Diseases (NIAID) selected USAMRIID rPA candidate for Phase 1 clinical trials

    • IND submitted in 2QFY03 in support of Phase I and II clinical trials

    • Phase I trial to be initiated 2/3Q FY03

  • USAMRIID rPA candidate and UK rPA candidate also part of long-term NIAID strategy for 25M dose stockpile

Assembly and action of anthrax toxin


Cb 31 medical countermeasures for brucella continuing dto l.jpg
CB.31 Medical Countermeasures for Brucella Candidate(Continuing DTO)

Brucellae in murine macrophage

  • Brucellosis

    • Nonspecific febrile illness

    • Low infectious dose, highly infectious by aerosol

    • Antibiotic resistance may limit treatment options

  • Vaccine Candidate

    • MNPH1 – live attenuated deletion mutant

    • Orally administered

    • Demonstrated proof of concept for protective efficacy in NHPs


Cb 34 recombinant plague vaccine continuing dto l.jpg
CB.34 Recombinant Plague Vaccine Candidate(Continuing DTO)

  • Plague: Tech base research generated two recombinant vaccine candidates

    • Both rely on F1 and V antigens

    • U.S. candidate is a recombinantly produced fusion protein

    • UK candidate is a combination of the two individually produced proteins

  • Technical progress:

    • Demonstrated 80% efficacy in non-human primates against 2.8 x 104 colony forming units (CFU)

    • Transitioned F1-V vaccine candidate to technology development pre-acquisition phase


Non dto supporting efforts bacterial vaccines l.jpg
Non-DTO Supporting Efforts Candidate(Bacterial Vaccines)

  • Anthrax

    • Further define pathogenesis of anthrax infection

    • Evaluate other known antigens, new adjuvants, and delivery systems

    • Employ functional genomics effort to identify new virulence determinants

  • Plague

    • Characterize the host immune response

    • Plan and develop the next-generation plague vaccine through identification of new protective immunogens

    • Define the genetic diversity and pathogenesis of natural plague isolates


Non dto supporting efforts bacterial vaccines16 l.jpg
Non-DTO Supporting Efforts Candidate(Bacterial Vaccines)

  • Glanders and Melioidosis

    • Develop an animal model of aerosolized glanders infection

    • Determine the mechanisms of immunity and establish correlates of immunity

    • Identify new virulence determinants

      • Potential vaccine candidates for protection against glanders

      • Evaluate the basis for virulence of Burkholderia mallei and B.pseudomallei by genetic and molecular methods


Non dto supporting efforts bacterial therapeutics l.jpg
Non-DTO Supporting Efforts Candidate(Bacterial Therapeutics)

  • Licensed antibiotics/novel antimicrobials

    • Primary focus is evaluation of licensed and investigational antibiotics for efficacy against BW bacterial threats

    • Specific effort to evaluate a series of licensed antibiotics as a post-exposure treatment for plague

    • Demonstrated proof-of-concept for small molecule inhibitors of anthrax toxin

  • Immunotherapy/Immunomodulators

    • Passive prophylactic antibody treatment protects animals against aerosolized plague or anthrax

    • Evaluating compounds capable of priming the immune response


Slide18 l.jpg

Virology Candidate

Task Areas

Objective:Explore the development of candidate prophylactic and therapeutic medical countermeasures (i.e., vaccines and antivirals) against validated BW threat agents, using laboratory and appropriate animal models, and to demonstrate their capability for reducing mortality or incapacitation in animal models exposed to predicted or presumed battlefield doses of aerosolized viral BW agents.

JFOC(s) addressed:Medical Prophylaxis (OC) – Individual Protection (PC)

Medical Treatment (OC) – Restoration (PC)

*Note: DTO CB.25 Multiagent Vaccines for Biological Threats completed in FY02


Cb 25 multiagent vaccines for biological threats dto completed in fy02 l.jpg

To move away from this… Candidate

25 Shots

Plus Boosters

To this…

Marburg Virus

Botulinum

toxin

Or this…

Anthrax

Marburg-Ci67

Marburg-Musoke

Marburg-Ravn)

Ebola-Z

Ebola-S

“Panfilovirus vaccine”

CB.25 Multiagent Vaccines for Biological Threats(DTO completed in FY02)

  • A vaccine or delivery approach that can concurrently immunize an individual against a range of biological warfare threats.

    • Reduce vaccination schedules

    • Decrease production costs

    • Streamline regulatory requirements

  • RNA Replicon and DNA Vaccine


Slide20 l.jpg

CB.24 Medical Countermeasures for Multivalent Equine Encephalitis Viruses(Continuing DTO)

Live attenuated VEE vaccines derived by site-directed mutagenesis of a full length infectious cDNA clone

Identification of attenuating

mutations:

sequence of attenuated variants

Wild-type full-

pV3000

length cDNA clone

mutagenesis of conserved sequences

pBR322

Site-directed mutagenesis

e.g.,

Molecularly defined clone

with attenuating mutations

pV3526

RNA

Testing in

animal models

Virus Rescue (V3526 virus)

Multivalent VEE vaccine requirement can be met through the use of a single component vaccine (V3526), eliminating interference issues while greatly simplifying clinical trials and formulation issues


Cb 54 therapy for smallpox and other pathogenic orthopoxviruses new dto in fy03 l.jpg
CB.54 Therapy for Smallpox and Other Pathogenic Orthopoxviruses(New DTO in FY03)

  • Cidofovir, sold under the trade name Vistide™, is approved by the FDA for the treatment of cytomegalovirus retinitis in AIDS patients

  • Cidofovir inhibits the viral DNA polymerase, thus stopping the replication of smallpox and other pathogenic orthopoxviruses and disease progression

  • Clinical trials of cidofovir against smallpox are not possible (smallpox has been eradicated)

  • FDA licensure is possible under the new Animal Efficacy Rule

    • Variola and monkeypox primate models are proposed to demonstrate antiviral efficacy


Slide22 l.jpg

Non-DTO Supporting Efforts Orthopoxviruses(Viral Vaccines)

  • Multivalent Equine Encephalitis (VEE/EEE/WEE) Vaccine (MEEV)

    • Use infectious cDNA clone & site-directed mutagenesis technology from DTO CB.24 to rationally derive live-attenuated eastern & western equine encephalitis (EEE & WEE) vaccine components to be combined with V3526 candidate into a MEEV

    • Investigate and assess alternative vaccine technologies

  • Recent Accomplishments

    • Developed an EEE vaccine component based on the cleavage deletion mutation

    • Successfully tested one WEE vaccine component in mouse model for:

      • Protective response within 30 days of vaccination

      • Duration of immunity of 1 year


Non dto supporting efforts viral vaccines l.jpg
Non-DTO Supporting Efforts Orthopoxviruses(Viral Vaccines)

  • Filovirus Vaccine

    • Develop a multiagent vaccine capable of protecting against various Ebola (EBOV) and Marburg (MARV) viruses (panfilovirus vaccine)

    • Leverage vaccine platform technology from Multiagent Vaccine DTO (CB.25) & from outside collaboration

  • Next Generation Smallpox Vaccine

    • Leverage DNA vaccine approach from DTO CB.25 to identify orthopoxvirus immunogens that contribute to protective immunity

    • Test if a gene-based vaccine technology can serve as an alternative to the live-vaccinia virus vaccine, or as a prime to a vaccinia boost


Slide24 l.jpg

FDA-Approved Compounds Orthopoxviruses

DARPA

Academics

FDA

IND

NCI-DTP library

Commercial Sources

Combinatorial Lib.

Primates

Mouse Model

Commercial Sources

Academics

Cell-Based Assay

In Vitro Evaluation

Modeling

Lead optimization

Screening

Lead Identification

In Vitro Evaluation

Assay Development

Target Identification

Target Validation

Non-DTO Supporting Efforts(Viral Therapeutics)


Slide25 l.jpg

Non-DTO Supporting Efforts Orthopoxviruses(Viral Therapeutics)

  • Antivirals for Smallpox

    • Develop an oral therapeutic antiviral drug based on cidofovir to treat smallpox and other naturally occurring or genetically modified pathogenic orthopoxviruses

    • Develop a second therapeutic antiviral drug based on non-DNA polymerase target (recommendation from IOM)

  • Antivirals for Filoviruses

    • Identified filovirus targets

    • Develop high thorough-put screening assays

    • Identify lead compounds for filoviruses

    • Develop therapeutic antiviral drugs based on lead compounds


Slide26 l.jpg

Non-DTO Supporting Efforts Orthopoxviruses(Viral Therapeutics)

  • Immunotherapies for Filoviruses

    • Objectives

      • Develop immunotherapies for treatment for infection with the various filoviruses

      • Test therapeutic intervention in combination with immunotherapy

    • Technology

      • Murine monoclonals  humanized antibodies  production in plants (leverage ongoing DARPA transition effort)

      • Combinatorial library from survivor monkey/human  humanized antibodies

      • anti-EBOV equine IgG

      • Test intervention strategies to prevent and treat shock and hemorrhage


Slide27 l.jpg

Toxinology Orthopoxviruses

Task Areas

Objective:Explore the development of candidate prophylactic and therapeutic medical countermeasures (i.e., vaccines, pretreatments, drugs and immunotherapies) against validated BW threat agents, using laboratory and appropriate animal models, and to demonstrate their capability for reducing mortality or incapacitation in animal models exposed to predicted or presumed battlefield doses of aerosolized toxin BW agents.

JFOC(s) addressed:Medical Prophylaxis (OC) – Individual Protection (PC)

Medical Treatment (OC) – Restoration (PC)


Cb 32 alternative vaccine delivery methods continuing dto l.jpg

SoloVent OrthopoxvirusesTM

MicromedicaTM micro-needles

OnVaxTM “swipe and go”

V. J. Sullivan, Ph.D.

Copyright BDT 2000

CB.32 Alternative Vaccine Delivery Methods(Continuing DTO)

BD Technologies Proprietary Alternate Vaccine Delivery Devices Currently Under Evaluation

  • Respiratory, transdermal, oral immunization that is safe, efficacious & expedient for stimulating mucosal and systemic immunity.

  • Simplify administration of the multiple vaccines.

  • Evaluation of multiple novel adjuvants in combination with alternate deliveries


Cb 46 recombinant ricin vaccine new dto in fy03 l.jpg
CB.46 Recombinant Ricin Vaccine Orthopoxviruses(New DTO in FY03)

Ricin: Classical approaches to producing a ricin toxoid vaccine proved unsuitable

  • Recombinant expression vectors will be used to produce mutated A-chain immunogens capable of protecting against ricin toxicity

  • Technical progress:

    • Designed, expressed, purified and partly characterized ricin vacine candidates

    • Lead candidate lacks enzyme activity and protects mice against ricin lethality

    • Lead candidate is stable, monodisperse monomer under physiological conditions with a reduced tendency to self-aggregate


  • Slide30 l.jpg

    Non-DTO Supporting Efforts Orthopoxviruses(Toxin Vaccines)

    • Toxin vaccines

      • Recombinant candidates for BoNT serotypes A, B, C1, E, and F

        (previous DTO)

        • Candidates transitioned to advanced development

        • Effort limited to support of advanced developer

      • Staphylococcal enterotoxin (SE) A and B vaccines (previous DTO)

        • Candidates ready to transition

        • Effort limited to stability analysis on pilot lots for use in future clinical studies


    Non dto supporting efforts toxin therapeutics l.jpg

    POST-EXPOSURE Orthopoxviruses

    TREATMENTS

    (5-10 years out)

    PRETREATMENTS

    (5 years out)

    Passive

    Immuno-

    therapy

    Receptor Antagonists

    Scavenge Free Toxin

    Active-site

    Inhibitors

    Protect SNAREs

    Rescue SNAREs

    NEURON DRUG DELIVERY

    (10-15 years out)

    Bot Hc Delivery Vehicle

    Streptolysin-O

    Non-DTO Supporting Efforts(Toxin Therapeutics)

    • Toxin therapeutics

      • Therapeutics for

        botulinum

        neurotoxins

      • Current major efforts

        • Active site inhibitors

        • Immunotherapy (MAbs)

        • Expand structural biology and high performance computing capabilities and access to compound libraries


    Non dto supporting efforts toxin therapeutics32 l.jpg
    Non-DTO Supporting Efforts Orthopoxviruses(Toxin Therapeutics)

    • Therapeutics for exposure to

      SEs

      • Block T-cell activation

      • Block SE-stimulated cytokine

        release

    • Therapeutics for exposure to

      Ricin

      • Basic research effort


    Slide33 l.jpg

    Diagnostic Technologies Orthopoxviruses

    Task Area

    Objective:Explore the development of technology candidates (reagents, protocols and devices) for inclusion into a deployable state-of-the-art identification and diagnostic system that integrates multiple methods for the identification of potential BW agents and the diagnosis of diseases they cause. The technology aim is to develop and integrate technologies so they will be capable of identifying multiple independent biomarkers from different agents simultaneously.

    JFOC(s) addressed:Medical Diagnostics (OC) – Restoration (PC)

    Med and Env Surveillance (OC) – Contamination Avoidance (PC)

    *Note: DTO CB.26 Common Diagnostic Systems completed in FY02


    Cb 26 common diagnostic systems dto completed in fy02 l.jpg
    CB.26 Common Diagnostic Systems Orthopoxviruses(DTO completed in FY02)

    Common Diagnostic Systems

    Delivered by S&T Program

    • Milestone A in FY01

    • Technology Data Package on evaluation of diagnostic technologies in support of JBAIDS

    • Continuing to transition reagents and assays to the Critical Reagents Program

    • Provides capability to rapidly identify exposure to BW and infectious disease agents

    • Portable nucleic acid analysis system:

      • Specimen processing, gene detection device, reagents, protocols

      • Capable of simultaneous detection of multiple agents


    Cb 47 improved immunodiagnostic platform new dto in fy03 l.jpg
    CB.47 Improved Immunodiagnostic Platform Orthopoxviruses(New DTO in FY03)

    Technology Options

    • Adjunct to nucleic acid detection

      • Primarily for the detection and identification of toxin threats

      • Also provides confirmatory assay for other medical diagnostic tests

    Time-Resolved Fluorescence

    Electrochemiluminescence (ECL) Reaction - First Generation Device - ORIGEN®

    Magnetic Field Detection

    Luminex


    Slide36 l.jpg

    Non-DTO Supporting Efforts Orthopoxviruses(Diagnostics Technologies)

    Evolutionary Strategy

    • Strategic Plan

      • Assay development

      • Identification of novel biological targets

      • Testing and evaluation

      • Technology assessment

    2002

    Portable Rapid Nucleic

    Acid Analysis System (Live Agents) Block I (CB.26)

    Improved Immunodiagnostic System (Toxins) Block II (CB.47)

    2004

    Integrated

    Diagnostic Systems

    Block III

    2007+


    Slide37 l.jpg

    Genetically Engineered Threats Orthopoxviruses

    Countermeasures Task Area

    Objective:Identify, group, prioritize, and assess the medical impact of non-traditional toxins, virulence factors, and genetically engineered microbes as BW threat agents. The information generated from research efforts under the thrust area will be used to direct the development of medical countermeasures and diagnostics against the most plausible and dangerous novel or emerging BW threats.

    JFOC(s) addressed:Medical Prophylaxis (OC) – Individual Protection (PC)

    Medical Treatment (OC) – Restoration (PC)

    Medical Diagnostics (OC) – Restoration (PC)


    Slide38 l.jpg

    DARPA Transition of BW Defense Programs Orthopoxviruses

    Thrust Area

    • Objective:Pursue technological advancement of novel medical countermeasures and diagnostic technologies initially developed through the Defense Advanced Research Projects Agency (DARPA) that will protect the warfighter from BW agents and provide increased operational capabilities.

    • Specifically, these promising initiatives will be developed to demonstrate proof-of-concept in appropriate animal models and include: novel, broad-spectrum therapeutics; the application of gene shuffling technology to DNA vaccine development; plant-based production of vaccine antigens and antibodies by expressing plague antigens and Ebola monoclonal antibodies in transformed plants; and a hand-held, tissue based biosensor through step-wise development of B-cell lines for relevant pathogens and multi-channel sensors.

    • JFOC(s) addressed:Medical Prophylaxis (OC) – Individual Protection (PC)

    • Medical Treatment (OC) – Restoration (PC)

    • Medical Diagnostics (OC) – Restoration (PC)

    • Status: Nine programs selected to date


    Roadmap vaccines l.jpg

    CB.34 Plague Orthopoxviruses

    Licensed Plague

    Plague Vaccine

    Licensed NGAV

    Roadmap(Vaccines)

    98 99 00 01 02 03 04 05 06 07 08 09 10 11 12 13

    Vaccine Technologies S&T Program

    CB.25 Multiagent

    CB.32 Needle-less Delivery

    CB.31 Brucella

    Brucella Vaccine

    CB.24 Multivalent VEE

    Multivalent VEE Vaccine

    Multivalent VEE Vaccine

    CB.33 rPA

    Next Gen Anthrax Vaccine (NGAV)

    CB.46 Ricin

    Ricin Vaccine

    FDA Licensed Vaccine Procurement

    Tech Base

    VEE – Venezuelan Equine Encephalitis

    rPA – recombinant Protective Antigen

    Developmental

    Un-funded Developmental

    Partially funded Developmental


    Roadmap diagnostics and therapeutics l.jpg
    Roadmap Orthopoxviruses(Diagnostics and Therapeutics)

    98 99 00 01 02 03 04 05 06 07 08 09 10 11 12 13

    Diagnostic Technologies S&T Program

    CB.26

    Common Diagnostic System

    JBAIDS Blk I

    CB.47

    Improved Immuno-diagnostic Platform

    JBAIDS Blk 2&3

    JBAIDS Blk 2&3

    Therapeutic Technologies S&T Program

    Therapy for Smallpox & other Pathogenic Orthopoxviruses

    CB.54

    Therapy for Smallpox & other Pathogenic Orthopoxviruses

    FDA Approval of Cipro® for use after exposure to inhalation anthrax (Aug 2000)

    Tech Base

    Procurement

    JBAIDS – Joint Bio Agent Identification & Diagnostic System

    CDS – Common Diagnostic Systems for Bio Threats & Endemic Infectious Diseases

    Developmental

    Un-funded Developmental

    Partially funded Developmental

    Unfunded Procurement


    Fy03 congressional interest medical s t funding increases 20 4m l.jpg
    FY03 Congressional Interest Orthopoxviruses(Medical S&T Funding Increases: +$20.4M)

    • Engineered Pathogen Identification and Countermeasures Program (“Bug to Drug”) (Sarnoff Corporation): +$5.0M

    • Monoclonal Antibody-based Technology “Heteropolymer” (HP) System (EluSys Therapeutics, Inc.): +$1.0M

    • Bioadhesion Research (Ligocyte Pharmaceuticals, Inc.): +$1.8M

    • Mustard Gas Antidote (Mustard Consortium): +$2.1M

    • Needleless Delivery Methods for Recombinant Protein Vaccines (BD Technologies): +$1.0M

    • Vaccine Stabilization (U of Kansas): +$1.5M

    • Organic Vaccine Production (TBD): +$2.5M

    • Portable Biochip Analysis System (Cleveland Clinic): +$1.8M

    • Piezoelectric Dry Powder Inhalation Device (U. of Pitt) : +$1.7M

    • Bioprocessing Initiative (U. of Nebraska Lincoln): +$2.0


    Cooperation with the department of health and human services dhhs l.jpg
    Cooperation with the Department of Health and Human Services (DHHS)

    • NIAID/CDC/FDA anthrax therapeutics

    • NIAID/USAMRIID/JVAP rPA clinical trials

    • NIAID/USAMRMC/USAMRIID Biodefense Campus

      • Program coordination

      • Program management

      • Infrastructure

    • USAMRIID/CDC

      • Smallpox research program

      • Anthrax antibodies


    Medical biological defense future trends l.jpg
    Medical Biological Defense Future Trends (DHHS)

    • Countermeasures for Genetically Engineered Microbes

      • Genomic sequencing of BW threat agents to identify and understand virulence factors, toxins and drug resistance genes

    • Immunomodulators and Therapies

      • Alternatives to agent-specific vaccines or therapies

    • Multiagent Vaccines

      • Alternative to one vaccine for one BW threat agent

    • Alternative vaccine delivery strategies

      • Immunization via mucosal and transdermal routes

    • Early markers of infection/host response


    ad